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Abstract
Background Implantable cardioverter defibrillators (ICDs)
are designed to deliver shocks or antitachycardia pacing
(ATP) in the event of ventricular arrhythmias. During
follow-up, some ICD recipients experience the sensation
of ICD discharge in the absence of an actual discharge
(phantom shock). The aim of this study was to evaluate
the incidence and predictors of phantom shocks in ICD
recipients.
Methods Medical records of 629 consecutive patients with
ischaemic or dilated cardiomyopathy and prior ICD implan-
tation were studied.
Results With a median follow-up of 35 months, phantom
shocks were reported by 5.1 % of ICD recipients (5.7 % in
the primary prevention group and 3.7 % for the secondary
prevention group; p0NS). In the combined group of primary
and secondary prevention, there were no significant predic-
tors of the occurrence of phantom shocks. However, in the
primary prevention group, phantom shocks were related to a
history of atrial fibrillation (p00.03) and NYHA class <III
(p00.05). In the secondary prevention group, there were no
significant predictors for phantom shocks.
Conclusion Phantom shocks occur in approximately 5 % of
all ICD recipients. In primary prevention patients, a relation
with a history of atrial fibrillation and NYHA class <III
were significant predictors for the occurrence of phantom
shocks. In the secondary prevention patients, no significant
predictors were found.
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Introduction
Implantable cardioverter defibrillators (ICD) are designed to
prevent sudden cardiac death (SCD) by converting ventric-
ular arrhythmias into a normal rhythm by the use of anti-
tachycardia pacing (ATP) or shock therapy. After several
primary and secondary prevention trials, the ICD has proven
efficacy in the prevention of SCD. Following the current
guidelines, both patients with ischaemic or dilated cardio-
myopathy (CMP) and a left ventricular ejection fraction
(LVEF) ≤35–40 % (primary prevention), and patients who
have already survived ventricular fibrillation or ventricular
tachycardia with haemodynamic instability (secondary pre-
vention) are candidates for ICD implantation. [1–4] Despite
improvements in the ICD technology, complications are still
common. [5] One of the least known complications is phan-
tom shock. In 1992, Kowey et al. described the first patient
to present with the experience of a shock without an actual
ICD discharge. [6] The incidence of phantom shocks in ICD
recipients has remained relatively unknown, as are the risk
factors for its appearance.
The aim of this study was to evaluate the incidence and
predictors of phantom shocks in ICD recipients with ischae-
mic or dilated CMP.
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All patients with ischaemic or dilated CMP who received an
ICD between January 2006 and December 2009 at the
Medisch Spectrum Twente, Enschede, the Netherlands were
selected from the hospital database. The indications for ICD
implantation were ischaemic or dilated cardiomyopathy
with an LVEF ≤35–40 % (primary prevention) or prior
ventricular fibrillation or ventricular tachycardia with hae-
modynamic instability according to the European guidelines
(secondary prevention). [4] Demographic, clinical, and
follow-up data were collected by careful review of hospital
records. After implantation, regular visits to the ICD outpa-
tient clinic were scheduled every 3–6 months and after every
experienced ICD discharge. Phantom shocks were defined
as the experience of an ICD discharge reported by the
patient, without an actual ICD discharge seen by device
interrogation.
Statistical analyses
Continuous variables are presented as mean ± SD or median
(range) as appropriate, and categorical data are summarised
as frequencies and percentages. Differences in clinical char-
acteristics between groups were analysed using Student’s
T-test, the Wilcoxon signed-rank test, and chi square or
Fisher’s exact test, as appropriate. The time course was
estimated by the Kaplan-Meier method. To examine the risk
factors, each variable was first entered into a univariate model,
and those found to be significant at a level of P < 0.20 were
then entered into the multivariate Cox regression analysis.
Subsequently, non-significant variables were removed, one
by one, until the model had significantly deteriorated as indi-
cated by the -2 log likelihood.
Results
Demographics
Data from 629 consecutive ICD recipients (age 64.0 years,
LVEF 29.6, 81.4 % male, 68.9 % ischaemic aetiology) were
collected. In total, 441 patients (70.1 %) received the ICD
for primary prevention reasons. The median follow-up was
35.0±13.6 months.
Influence of clinical variables on occurrence of phantom
shocks
A phantom shock was experienced by 32 patients (5.1 %).
The median time to phantom shock was 13 months (range
0–43 months; Fig. 1). There was a trend for phantom shock
to occur earlier in patients who received their ICD for
secondary prevention (p00.14). Overall, after univariate
and multivariate analysis, there was no significant predictor
of the occurrence of phantom shocks. Statistical trends were
found for a history of atrial fibrillation (p00.11), New York
Heart Association (NYHA) class <III (p00.07) and prior
appropriate shock therapy (p00.09). All data can be found
in Table 1.
Primary prevention patients
In the primary prevention group (n0441; Table 2), 25
patients (5.7 %) experienced a phantom shock. The median
time to shock was 12 months (range 0–45 months). After
univariate analysis, there was a significant relation between
a history of atrial fibrillation and the occurrence of phantom
shocks (p00.04). Statistical trends were found for NYHA
class <III (p00.07), ischaemic aetiology of cardiomyopathy
(p00.18), and prior shock therapy (p00.19), especially appro-
priate shock therapy (p00.11). After multivariate analysis, a
history of atrial fibrillation (p00.03) and NYHA class <III
(p00.05) remained significant.
Secondary prevention patients
In the secondary prevention group (n0187; Table 3), 7
patients (3.7 %) experienced a phantom shock. The median
time to shock was 1 month (range 0–33 months). There
Fig. 1 Time to phantom shock in months, stratified by indication of
ICD implantation
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were no significant predictors for the occurrence of phantom
shocks.
Discussion
In our cohort, during a mean follow-up of 35 months, 5.1 %
of the ICD recipients experienced phantom shocks. In the
primary prevention group, phantom shocks occurred in
5.7 % versus 3.7 % in the secondary prevention group.
Regarding risk factors, in the primary prevention group
there was a significant relation between occurrence of phan-
tom shocks and a history of atrial fibrillation and NYHA
class <III. In the secondary prevention group, no significant
predictors were found.
Phantom shocks were first reported by Kowey et al. in
1992, [6] yet the incidence of phantom shocks remains
unknown. There are only two cohort studies dealing with
Table 1 Demographic differen-
ces stratified by phantom shocks
All variables are in numbers
(percentages) unless otherwise
specified. LVEF left ventricular
ejection fraction, NYHA New
YorkHeart Association functional
class, ATP antitachycardia pacing
Phantom shock (n032) No phantom shock (n0597) p-value
Age (years ±SD) 62.4±13.0 64.1±9.8 0.36
Male gender 25 (78.1 %) 487 (81.6 %) 0.63
LVEF (% ±SD) 27.7±3.6 27.2±4.5 0.57
Aetiology 0.24
Ischaemic 25 (78.1 %) 407 (68.3 %)
Non-ischaemic 7 (21.9 %) 189 (31.7 %)
Indication 0.31
Primary prevention 25 (78.1 %) 416 (69.7 %)
Secondary prevention 7 (21.9 %) 181 (30.3 %)
History
Hypertension 8 (25.0 %) 145 (24.4 %) 0.94
COPD 3 (9.4 %) 63 (10.6 %) 1.00
Diabetes mellitus 5 (15.6 %) 132 (22.2 %) 0.38
Atrial fibrillation 13 (40.6 %) 165 (27.7 %) 0.11
NYHA class <III 5 (15.6 %) 185 (31.5 %) 0.07
Prior shock therapy 10 (31.3 %) 122 (20.4 %) 0.23
Appropriate 8 (25.0 %) 78 (13.1 %) 0.09
Inappropriate 4 (12.5 %) 49 (8.2 %) 0.50
Prior ATP therapy 8 (25.0 %) 105 (17.6 %) 0.40
Table 2 Demographic differen-
ces in primary prevention ICD
recipients, stratified by phantom
shocks
All variables are in numbers
(percentages) unless otherwise
specified. LVEF left ventricular
ejection fraction, COPD chronic
obstructive pulmonary disease,
NYHA New York Heart
Association functional class,
ATP antitachycardia pacing
Phantom shock (n025) No phantom shock (n0416) Puni Pmulti
Age (years ±SD) 62.4±12.1 63.8±9.5 0.49 NS
Male gender 18 (72.0 %) 341 (81.4 %) 0.21 NS
LVEF (% ±SD) 28.8±13.5 25.6±12.6 0.22 NS
Aetiology 0.18 NS
Ischaemic 19 (76.0 %) 260 (62.5 %)
Non-ischaemic 6 (24.0 %) 156 (37.5 %)
History
Hypertension 6 (24.0 %) 91 (21.9 %) 0.81 NS
COPD 2 (8.0 %) 49 (11.8 %) 0.76 NS
Diabetes mellitus 5 (20.0 %) 99 (23.8 %) 0.36 NS
Atrial fibrillation 11 (44.0 %) 107 (25.8 %) 0.04 0.03
NYHA class <III 5 (20.0 %) 158 (38.0 %) 0.07 0.05
Prior shock therapy 7 (28.0 %) 67 (16.1 %) 0.19 NS
Appropriate 5 (20.0 %) 38 (9.1 %) 0.11 NS
Inappropriate 3 (12.0 %) 34 (8.2 %) 0.59 NS
Prior ATP therapy 6 (24.0 %) 57 (13.7 %) 0.23 NS
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phantom shocks in ICD patients. In an abstract, Swygman et
al. described a cohort of 445 patients with a median follow-
up of 28 months where phantom shocks occurred in 30
(6.7 %) patients [7] and in a recent study Wojcicka et al.
described 55 young ICD patients in which phantom shocks
occurred in 21 % of the patients. [8] In our cohort, phantom
shocks were experienced by 5.1 %, which is comparable
with Swygman’s cohort, but lower than Wojcicka’s cohort.
Our cohort is not comparable with that described by Woj-
cicka in terms of age and disease aetiology.
In the primary prevention group in our cohort, a history
of atrial fibrillation (especially paroxysmal atrial fibrillation)
and NYHA class <III were significantly related to the oc-
currence of phantom shocks. In the literature, no supportive
data were found for these relations. A possible explanation
for the relation between a history of atrial fibrillation and the
experience of phantom shocks is the misinterpretation of the
symptoms associated with the occurrence of atrial fibrilla-
tion. [9, 10]
It is suggested that anxiety and depression play a role in
the occurrence of phantom shocks. In a case–control study
by Prudente et al., it was shown that patients with phantom
shocks had higher levels of anxiety and depression than the
controls. [11] However, since the data were collected after
the (phantom) shock occurred, it is difficult to determine
whether the higher levels of anxiety and depression trig-
gered the experience of phantom shock or visa versa. Swyg-
man et al. noticed that phantom shocks mainly occurred in
the first 6 months after implantation. [7] Similarly, in our
study, most phantom shocks occurred early after implanta-
tion. A possible explanation for this might be the higher
anxiety levels during the first months as a result of the
implantation procedure or (in the secondary prevention
group) a recently survived cardiac arrest. In our study we
did not see a statistically significant difference between the
primary and secondary prevention group regarding the me-
dian time to the phantom shock; however, this can be due to
the small number of patients with phantom shocks in the
secondary prevention group.
After appropriate shock therapy, it has been shown that
levels of self-reported anxiety rise ; [12] it could therefore be
hypothesised that also prior ICD therapy might be associat-
ed with the occurrence of phantom shocks. In our study,
shock therapy (both appropriate or inappropriate) was more
frequent in the group with phantom shocks, but this did not
reach statistical significance. Longer follow-up may be
wanted, since in most of the included patients ICD therapy
occurred in the last phase of the follow-up. In the literature,
the relation between appropriate shock therapy and phantom
shocks is not clear either. Neither Swygman nor Jacob et al.
found a relation with single appropriate shocks. [7, 13]
Electrical storms, however, were related to higher anxiety
levels and phantom shocks.[13] Prospective studies are
needed to answer questions about the influence of shock
therapy, the psychological determinants of phantom shocks
in the ICD population, consequences for post-implantation
care and possible psychological intervention [14] to reduce
the number of patients experiencing phantom shocks.
Limitations
Our study is limited by several factors. The most important
limitation is the observational design of this study, and
therefore the lack of (prospective) psychological data and
the possibility of underestimation of the occurrence of phan-
tom shocks. Other limitations are the relatively low number
Table 3 Demographic differen-
ces in secondary prevention ICD
recipients, stratified by phantom
shocks
All variables are in numbers
(percentages) unless otherwise
specified. LVEF left ventricular
ejection fraction, COPD chronic
obstructive pulmonary disease,
NYHA New York Heart
Association functional class,
ATP antitachycardia pacing
Phantom shock (n07) No phantom shock (n0180) Puni
Age (years ±SD) 62.4±17.0 64.7±10.5 0.74
Male gender 7 (100 %) 146 (80.7) 0.35
LVEF (% ±SD) 22.2±17.2 41.8±25.9 0.22
Aetiology 1.00
Ischaemic 6 (85.7 %) 147 (81.7 %)
Non-ischaemic 1 (14.3 %) 33 (18.3 %)
History
Hypertension 2 (28.6 %) 54 (30.3 %) 1.00
COPD 1 (14.3 %) 14 (7.8 %) 0.45
Diabetes mellitus 0 (0.0 %) 33 (18.4 %) 0.36
Atrial fibrillation 2 (28.6 %) 58 (32.2 %) 1.00
NYHA <III 0 (0.0 %) 27 (14.9 %) 0.60
Prior shock therapy 3 (42.9 %) 55 (30.4 %) 0.68
Appropriate 3 (42.9 %) 40 (22.1 %) 0.20
Inappropriate 1 (14.3 %) 15 (8.3 %) 0.47
Prior ATP therapy 2 (28.6 %) 48 (26.6 %) 1.00
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of patients with phantom shocks, especially in the secondary
prevention group and the relatively short follow-up.
Conclusion
With amedian follow-up of 35months, phantom shocks occur
in 5 % of the ICD recipients. In the primary prevention group,
a history of atrial fibrillation and/or NYHA class <III was
related to the occurrence of phantom shocks. In the secondary
prevention patients, no significant predictors were found.
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